Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-Release Buprenorphine (XRB) Initiation in Jail
NCT06051890Phase 4Recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Percentage of participants released from jail with at least 7 days of buprenorphine in their system. Started Jun 2025; status: recruiting.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06051890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051890.